19:54 , May 25, 2018 |  BioCentury  |  Emerging Company Profile

Universal ambitions

Emergex Vaccines Holdings Ltd. is making synthetic peptide vaccines it thinks could provide universal immunity -- and at a fraction of the time and cost of traditional vaccine development. Emergex launched in 2016 with IP...
23:53 , Feb 22, 2018 |  BC Innovations  |  Product R&D

Shooting for the universe

CureVac AG is bringing a new modality to the race for a universal flu vaccine with an mRNA program backed by a grant from the Bill & Melinda Gates Foundation. While the company believes its...
07:00 , Apr 4, 2016 |  BC Week In Review  |  Clinical News

Multimeric-001 Universal Flu Vaccine: Completed Phase IIb enrollment

BiondVax completed enrollment of 224 volunteers in a double-blind, Hungarian Phase IIb trial comparing intramuscular M-001 plus H5N1 influenza vaccine vs. H5N1 influenza vaccine alone. BiondVax Pharmaceuticals Ltd. (Tel Aviv:BVXV; NASDAQ:BVXV), Ness Ziona, Israel  ...
07:00 , Aug 10, 2015 |  BC Week In Review  |  Clinical News

Multimeric-001 Universal Flu Vaccine: Additional Phase II data

An analysis of blood plasma samples from 120 elderly volunteers aged 65 and older who were treated 3 years ago in the double-blind, Israeli Phase II BVX-005 trial showed that >=50% of subjects who received...
07:00 , Aug 3, 2015 |  BC Week In Review  |  Clinical News

Multimeric-001 Universal Flu Vaccine: Preliminary Phase II data

Preliminary data from the double-blind, placebo-controlled, Israeli Phase II BVX-006 trial in 36 volunteers ages 50-65 showed that 3 intramuscular injections of 1 mg M-001 every 21 days followed by an injection of the 2014/2015...
07:00 , Oct 21, 2013 |  BC Week In Review  |  Company News

BiondVax, Isconova, Retroscreen Virology, Seek Ltd., Medicines and Healthcare products Regulatory Agency (MHRA), National Center for Epidemiology, Norwegian Ins

The Universal Influenza Vaccines Secured (UNISEC) consortium will receive a €6 million ($8.1 million) grant from EU's Framework Programme 7 (FP7) to develop a universal influenza vaccine. UNISEC comprises the four companies, the five institutes...
07:00 , Oct 29, 2012 |  BC Week In Review  |  Company News

BiondVax, MonoSol Rx deal

BiondVax and MonoSol partnered to develop a room temperature stable formulation of BiondVax's Multimeric-001 Universal Flu Vaccine ( BVX-M001 ) using MonoSol's PharmaFilm thin film technology. The companies said the resulting formulation could be administered...
08:00 , Feb 27, 2012 |  BC Week In Review  |  Clinical News

Multimeric-001 Universal Flu Vaccine: Phase II data

The double-blind, Israeli Phase II BVX-005 trial in 120 elderly volunteers aged 65 and older showed that 2 doses of 500 µg Multimeric-001 Universal Flu Vaccine given 21 days apart were safe and well tolerated,...
07:00 , Jun 20, 2011 |  BC Week In Review  |  Clinical News

Multimeric-001 Universal Flu Vaccine: Phase IIa data

A double-blind, Israeli Phase IIa trial in 200 healthy volunteers showed that 2 doses of 500 µg adjuvanted Multimeric-001 Universal Flu Vaccine met the co-primary endpoint of significantly increasing IgG antibodies from baseline to day...
00:31 , Jun 17, 2011 |  BC Extra  |  Clinical News

BiondVax vaccine meets Phase II influenza endpoint

BiondVax Pharmaceuticals Ltd. (Tel Aviv:BNDX) said its Multimeric-001 Universal Flu Vaccine met the co-primary endpoint of significantly increasing IgG antibodies from baseline to day 42 vs. adjuvanted placebo (p<0.05) in a Phase IIa trial to...